The Efficacy of Ibogaine in the Treatment of Addiction; an open label, single fixed dose pilot-study of the efficacy of ibogaine in opioid-dependent subjects

This open-label, single fixed dose pilot-study trial (n=12) aimed to investigate the efficacy of ibogaine in treating opioid dependence.

Conducted by Radboud UMC in the Netherlands, the study assessed the short and long-term effects of a single administration of ibogaine on craving and substance use over a six-month follow-up period. Secondary objectives included examining the effects of ibogaine on cognitive processes linked to craving, evaluating dropout rates during treatment, and assessing safety during acute in-hospital opioid withdrawal and post-treatment.

Participants, aged 23 to 60, were opioid-dependent individuals wishing for detoxification and lasting abstinence. The trial found promising results in reducing relapse and subjective craving after detoxification. However, it excluded patients with certain medical conditions, including cardiac illness and severe major depressive disorder, as well as pregnant individuals and those actively suicidal. The trial received authorisation from the Competent Authority in the Netherlands and ethical approval on November 10, 2014.

Topic Opioid Use Disorder Addiction
Compound Ibogaine
Country Netherlands
Visit trial
Status Completed
Results Published Yes
Start date 10 November 2014
End date 30 April 2021
Phase Phase II
Design Open
Type Interventional
Generation First
Participants 12
Sex All
Age 23- 60
Therapy Yes

Trial Details

This open-label trial (n=12) investigated the efficacy of ibogaine in treating opioid dependence, assessing its effects on craving and substance use over a six-month period. Conducted by Radboud UMC in the Netherlands, it found promising results in reducing relapse and subjective craving after detoxification.

NCT Number 2014-000354-11

Sponsors & Collaborators

Radboud University
This company page is linked to research but doesn't have a full profile yet.

Papers

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients
This pharmacokinetic study (n=14) on ibogaine (700mg/70kg) for opioid use disorder (OUD) finds significant variability in ibogaine clearance, strongly correlated with CYP2D6 genotype. Ibogaine plasma concentrations correlate with QTc prolongation and cerebellar effects, while neither ibogaine nor noribogaine correlate with the severity of opioid withdrawal symptoms.

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
This open-label observational study (n=14) investigated the safety profile of ibogaine (700mg/70kg) for patients with opioid use disorder who were undergoing acute opioid withdrawal. Although patients experienced mild withdrawal symptoms and transient well-tolerated psychomimetic effects, they exhibited abnormal patterns in heart rhythm that constituted an adverse level of cardiovascular risk. This study indicates that even a low-dose administration of ibogaine requires strict cardiac monitoring, and should be restricted to well-controlled settings.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.